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OBJECTIVES: Three formulations of leuprolide, an established LH-RH agonist are
used in the management of advanced prostate cancer. In order to inform clinical
practice, the economic impact of the different formulations and dosing schedules
were evaluated for Austria, Belgium, Czech Republic, Hungary, Italy, Latvia, The
Netherlands, Poland and Portugal.METHODS:Database searches identified 10 clin-
ical trials of leuprolide 1-monthly (1M), 3-monthly (3M) and 6-monthly (6M) with
Atrigel®, requiring 6, 4 and 2 hospital treatment visits respectively. Due to reported
comparable efficacy, safety and adherence, cost-minimisation analysis was con-
ducted. Costs of the product, specialist consultations and diagnostics (converted to
2010 euros) were considered during up to 12 months follow-up. The perspective
was that of public payers. RESULTS: The review showed that with the use of leu-
prolide 1M, 3M and 6M the respective percentage of patients achieving testosterone
suppression of 50ng/dl was 93.3%, 98.3% and 97.3% (p0.05). However, 6M was
the least cost treatment option, with average total annual costs from 788€ (Poland)
to 1839€ (Portugal). The 3M option was 2.5% (Hungary) to 37.6% (Belgium) higher
than 6M cost; while 1M formulation had the highest cost: 15.6% and 151.6% more
than 6M for those countries, respectively. The 3M option was 11.2% to 45.3% less
expensive than 1M. The cost drivers were the frequency of visits for injection and
monitoring. The study showed that up to 50% additional visits could be funded
with the savings resulting from switching eligible patients from 1M and 3M to 6M.
Results were robust in one-way sensitivity analyses, as well as probabilistic sensi-
tivity analysis. CONCLUSIONS: Leuprolide acetate with Atrigel® 1M, 3M and 6M
formulations offer comparable efficacy and safety. However, driven by the fre-
quency of visits, the 6-monthly formulation offers the greatest cost-savings for
prostate cancer patients in the European countries studied.
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THE ADJUVANT TREATMENT OF STAGE 3 COLON CANCER (ACC): AN INDIRECT
COST-MINIMISATION AND POPULATION NET HEALTH BENEFIT ANALYSIS OF
CAPECITABINE  OXALIPLATIN (XELOX) VS. IV 5-FU  FA  OXALIPLATIN
(FOLFOX)
Garside J, McNamara S, Millar D
Roche Products Limited, Welwyn Garden City, UK
OBJECTIVES: XELOX is the most utilised therapy for aCC in the UK. The aim of this
analysis was to assess and compare the population net health benefit (pNHB) of all
patients with aCC switching from the FOLFOX regimen to XELOX, from a UK Na-
tional Health Service (NHS) perspective. METHODS: An indirect comparison of the
NO16968 (XELOX) and MOSAIC (FOLFOX-4) trials was undertaken (where both reg-
imens were compared to i.v. 5-FU plus FA) showing XELOX to be non-inferior. A cost
minimisation approach was therefore taken. Drug costs were based on UK list
prices taken from the British National Formulary (BNF 61), and additional costs
such as administration costs, adverse event costs and pharmacy costs were taken
from NHS reference costs, the literature and previous technology appraisals. A
£20,000/QALY assumed displacement threshold was utilised to estimate the pNHB
provided. Uncertainty was explored via one-way sensitivity analyses. RESULTS:
Replacing FOLFOX-6 and FOLFOX-4 with XELOX saved £6490 and £9778 per patient
respectively, of which £2434 and £1534 came from drug acquisition costs. Over 60%
of the total savings were realised from reductions in the frequency of pharmacy use
and administration resource use. The savings realised from full implementation of
the XELOX regimen could be used by the NHS to generate more than 1000 QALYs
over the next 5 years. The costs of AEs were similar across all three regimens.
XELOX achieved savings of £3,400 per patient even when all parameters in the
sensitivity analysis were simultaneously set to the worse case scenarios.
CONCLUSIONS: XELOX has been demonstrated to be cost-effective and signifi-
cantly cost-saving versus FOLFOX-4 and FOLFOX-6 in aCC from an NHS perspec-
tive. Full conversion of all aCC patients to XELOX could offer the NHS substantial
financial savings and a significant pNHB of over 1000 QALYs over a 5 year period.
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COST MINIMIZATION ANALYSIS (CMA) OF CAPECITABINE/CISPLATIN (XP) VS.
5-FU/CISPLATIN (FP) REGIMENS IN ADVANCED GASTRIC CANCER (AGC)
TREATMENT IN THE ROMANIAN SETTING
Curescu S1, Stanculeanu DL2, Croitoru A3, Radu CP4
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OBJECTIVES: The objective was to compare the first-line therapy costs of
capecitabinecisplatin(XP) and 5-FUcisplatin (FP) in patients with AGC in the
Romanian health care system. METHODS: Due to similar efficacy as shown in the
study ML 17 032 (Kang et al.) a cost minimization analysis was performed (CMA).
Direct costs of the two alternative therapies were estimated based on the trial
results on actual dose and the number of administrations, and unit costs in Roma-
nian hospitals from payer perspective (National Health Insurance House). Adverse
event (AE) profiles were used to calculate costs of treating AEs. An expert panel
estimated typical treatment patterns and costs of treating major AEs. RESULTS: XP
arm patients received 5.2 cycles vs. 4.6 cycles in FP arm. The substitution of oral
capecitabine for infusional 5-FU reduced the number of hospital clinic visits by 17.6
(22.8 for FP versus 5.2 for XP). Drug costs were estimated to be ROL 5,230 greater in
the XP arm, but drug administration costs were ROL 5,904 lower, yielding a net cost
saving of ROL 674 per patient (1Euro4,2 ROL). Adverse event profiles were almost
similar: associated costs to treat AEs were less than ROL 270 per patient and were
lower in the XP arm by ROL 67. Total incremental cost was - ROL 741 in favor of XP
regimen. CONCLUSIONS: Oral capecitabine treatment is a cost-saving regimen for
AGC from Romanian public payer’s perspective.
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ECONOMIC EVALUATION OF PANITUMUMAB AND CETUXIMAB IN THE
TREATMENT OF PATIENTS WITH EGFR EXPRESSING MCRC WITH NON-
MUTATED (WILD-TYPE) KRAS IN GREECE: A COST MINIMIZATION ANALYSIS
Fragoulakis V1, Papagiannopoulou V2, Kourlaba G1, Ducournau P3, Maniadakis N1
1National School of Public Health, Athens, Greece, 2Amgen Hellas, Athens, Greece, 3Amgen
(Europe) GmbH, Zug, Switzerland
OBJECTIVES: Metastatic colorectal cancer (mCRC) accounts for a substantial eco-
nomic and clinical burden worldwide. The aim of the present study was to conduct
an economic evaluation in Greece comparing panitumumab with cetuximab in the
monotherapy treatment of patients with non-mutated (wild-type) KRAS, epider-
mal growth factor receptor (EGFR)-expressing mCRC. METHODS: Based on litera-
ture search, panitumumab and cetuximab are assumed to have similar efficacy,
hence a cost-minimization analysis was carried out from the third-payer-party
(Sickness Fund) and the National Health Service (NHS) perspective. A probabilistic
model was constructed to estimate the resource utilization and costs associated
with the management of patients receiving either therapy. Due to known differ-
ences in various settings regarding drug use, two type of analysis were undertaken:
one reporting “cost per mg” and another reporting “cost per vial”. Treatment cost
accounted for administration of second line chemotherapy, laboratory and bio-
chemical examinations and for hospitalization due to toxicity. Data on resource
utilization were collected from two oncology units in Greece and prices refer to
2011. Non parametric bootstrapping was employed to deal with uncertainty and to
estimate variability measures. RESULTS: From a third-payer-party perspective, it
was found that the mean 20-week total cost per patient for panitumumab and
cetuximab in the “per mg analysis” was €16,349 (95%CI: 16,036.7-16,637.8) and
€18,242 (95%CI: 17,902.4-18,597.9), respectively. The corresponding mean total
costs obtained in “per vial analysis” was €18,808 (95%CI: 18,437.7-19,161.7) and
€19,701 (95%CI: 19,358.6-20,053.1), respectively. From the NHS perspective, while
the mean total costs per patient were higher than for third party payers, versus
cetuximab, panitumumab was still associated with a 12.40% and 17.7% cost reduc-
tion in per-vial and per-mg analysis, respectively. CONCLUSIONS: In the Greek
NHS and Sickness Fund setting, panitimumab may represent a cost-saving option
compared with cetuximab in the management of patients with non-mutated (wild-
type) KRAS, epidermal growth factor receptor (EGFR)-expressing mCRC.
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CAPECITABINE PLUS OXALIPLATIN (CAPOX) VERSUS
FLUOROURACIL/LEUCOVORIN PLUS OXALIPLATIN (FOLFOX) IN STAGE III
COLON CANCER: A COST-MINIMIZATION ANALYSIS BASED ON REAL WORLD
COSTS IN THE NETHERLANDS
van Gils CWM, de Groot S, Redekop WK, Uyl-De Groot CA
Institute for Medical Techonology Assessment (iMTA), Rotterdam, The Netherlands
OBJECTIVES: Recent publications have demonstrated equal efficacy of capecit-
abine and fluorouracil/leucovorin in combination with oxaliplatin in the adjuvant
treatment of stage III colon cancer. It is stated that CAPOX and FOLFOX can be used
interchangeably. METHODS: A cost-minimization analysis was performed using a
Markov model, a two-year time horizon and a hospital perspective. Assuming
equal efficacy of CAPOX and FOLFOX, transition probabilities were based on the
MOSAIC trial (Andre et al., 2004 and 2009). Dutch real-world population-based
treatment and follow-up cost were calculated using a representative sample of 102
patients treated with oxaliplatin for stage III colon cancer in 19 hospitals in the The
Netherlands. Resource use was collected from the first administration of adjuvant
chemotherapy until disease progression (or end of follow-up). Costs of drug acqui-
sition, drug administration, patient monitoring, and adverse events were consid-
ered and reported in euro 2009. RESULTS: In Dutch practice, the median time on
adjuvant treatment was 24 weeks for both CAPOX and FOLFOX, as recommended in
the guidelines. Mean total costs were € 19,373 for CAPOX and € 31,324 for FOLFOX,
resulting in a significant overall cost savings of € 11,951 for CAPOX compared with
FOLFOX. Main savings resulted from administration costs (€ 8,460), due to in-
creased hospital admissions in the FOLFOX treatment as the administration of
fluorouracil involves a 48-hour continuous infusion. Other savings were obtained
from acquisition costs (€ 2181) and costs of managing adverse events (€ 1427).
Monitoring costs were comparable in CAPOX and FOLFOX. Probabilistic sensitivity
analysis confirmed the robustness of the results. CONCLUSIONS: CAPOX is cost-
saving in comparison with FOLFOX for the adjuvant treatment of stage III colon
cancer in a real-world setting in the The Netherlands. Considering the high inci-
dence of colon cancer in the The Netherlands, substantial overall savings can be
realized by routine use of CAPOX in this indication.
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POTENTIAL BENEFITS OF INTRODUCING A COMPANION DIAGNOSTIC IN
ADVANCED NON-SMALL CELL LUNG CANCER
Zaim R, Gaultney J, Redekop W, Uyl-de Groot C
Institute for Medical Technology Assessment, Erasmus University, Rotterdam, The Netherlands
OBJECTIVES: Gefitinib is a promising first-line treatment option in advanced non-
small cell lung cancer (NSCLC) patients with positive epidermal growth factor re-
ceptor tyrosine kinase (EGFR-TK) mutations. However, some patients with s`ensi-
tive´ EGFR-TK mutations and primary resistance do not respond to gefitinib
treatment. The objective of this early health technology assessment was to quan-
tify the potential health gain and cost consequences that would result with the
introduction of a companion diagnostic prior to first-line treatment of advanced
NSCLC patients with positive EGFR-TK mutations.METHODS:A Markov model was
designed to compare a companion diagnostic strategy (gefitinib or gemicitabine-
carboplatin) versus treating all patients with gefitinib (gefitinib for all). Model in-
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puts were taken from the IPASS trial, literature and publicly available sources. A
two-year time horizon (based on the IPASS) was applied to calculate incremental
costs, progression-free life years (PFLYs) and quality adjusted life years (QALYs).
The perspective of National Health Service (NHS) in England and Wales was used.
Sensitivity analyses were performed to assess uncertainty in the results. RESULTS:
Base-case results revealed that the companion diagnostic strategy was dominant
with improvements in effects (0.095 PFLYs, 0.020 QALYs) and reduction in costs
(-£774). Small differences in QALY estimates were a consequence of using health
utility inputs from second-line advanced NSCLC setting (intravenous treatment
only). The results were sensitive to the health utilities, probability of being a re-
sponder and sensitivity, specificity and cost of the companion diagnostic.
CONCLUSIONS: This early health technology assessment suggests that introduc-
ing a companion diagnostic prior to first-line advanced NSCLC treatment has the
potential to improve effectiveness and reduce costs compared to the gefitinib for all
strategy. Further research should aim at eliciting generic utility values to better
estimate the potential health benefits of targeted therapies in this setting.
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ECONOMIC EVALUATION OF SUNITINIB MALATE FOR THE FIRST-LINE
TREATMENT OF METASTARIC RENAL CELL CARCINOMA IN THE CHINESE
HEALTH CARE SETTING
Wu J1, Zhang N1, Dong P2
1Tianjin University, Tianjin, China, 2Pfizer China, Beijing, China
OBJECTIVES: To assess the cost-effectiveness of sunitinib malate as a first-line treat-
ment in metastatic renal cell carcinoma (mRCC) compared with sorafenib and inter-
feron-alfa (IFN-) in the Chinese healthcare setting.METHODS:A Markov model was
developed in Microsoft Excel® to simulate disease progression and determine out-
comes over 5 years of a hypothetical cohort of 1,000 patients with mRCC receiving
first-line treatment (in 6-week cycles, 4 weeks treatment plus 2 weeks off treat-
ment) with sunitinib compared with sorafenib as well as IFN-. The model param-
eters were derived from the Pivotal Study A6181034-A3, published literatures, gov-
ernment sources as well as clinical experts’ opinions. Only direct costs were
considered in terms of drug treatment, routine follow-up, severe adverse events,
disease progression, and costs of health care resources involved in the palliative
care of terminally-ill patients. Health outcomes were measured in LYs and QALYs.
The results were expressed as ICER and ICUR. Time horizon was 5 years and the
discount rate of 5%/year was applied to costs and effectiveness. Sensitivity analyses
were also performed. RESULTS: The results indicated that in terms of total average
cost per patient over 5 years, sunitinb was less costly (¥611,054) than sorafenib
(¥613,304), and more costly than IFN-(¥150,159). Concerning health outcomes, the
estimated gains for one patient treated with sunitnib over IFN- were 0.25 LYs and
0.29 QALYs, and over sorafenib were 0.09 LYs and 0.13 QALYs. The ICER and ICUR of
sunitinib versus IFN- were ¥1,837,954 per LY gained and ¥1,585,357 per QALY
gained, respectively. CONCLUSIONS: Results suggest that sunitinib has better clin-
ical efficacy compared to sorafenib and IFN-, and is a cost-saving alternative to
sorafenib as a first-line treatment for mRCC in China. When compared with IFN,
Sutent achieved better clinical outcomes with increased cost.
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COST EFFECTIVENESS OF FIRST LINE TYROSINE KINASE INHIBITOR
TREATMENT IN EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MUTATED
ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS: A MARKOV
MODEL
Borget I1, Vergnenegre A2, Chouaid C3
1Health Economic service, Biostatistic and Epidemiology Department, Villejuif, France, 2SIME,
Limoges, France, 3Service of Pneumology, Paris, France
OBJECTIVES: EGFR testing and first line tyrosine kinase inhibitor (TKI) for patients
with activating mutations is an option for the treatment of advanced non-small cell
lung cancer (NSCLC). There is few data’s on the cost-effectiveness of this strategy.
The objective of this study was to determine the incremental cost-effectiveness
ratio of first-line treatment with TKI compared to recommended chemotherapy
(cisplatin pemetrexed doublet) in patients with EGFR mutation. METHODS: A
Markov model was developed. Clinical outcomes were derived from the EURTAC
phase III trial comparing TKI to chemotherapy in first-line of NSCLC. Cost data were
estimated using individual data from French randomized clinical trial or prospec-
tive cohort, whereas utility scores derived from published data’s. Costs were lim-
ited to direct costs for medications, physician visits, hospitalizations and treat-
ment of adverse events. Analysis was limited to the period between treatment
initiation of until first progression. All costs were expressed in 2010 Euro. Sensitiv-
ity analyses were performed. RESULTS: First line treatment with TKI was more
effective than recommended chemotherapy (respectively 0.730 and 0.437 QALY),
but also more expensive (respectively 29 702 € and 18 796 € per patient). The incre-
mental cost-effectiveness ratio was then estimated at 37 221 €/QALY. Sensitivity
analyses showed the robustness of the results. CONCLUSIONS: Based on these
data, first line treatment based on TKI appeared as cost effective in EFGR mutated
advanced NSCLC patients.
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ECONOMIC EVALUATION OF GEFITINIB FOR FIRST-LINE TREATMENT OF EGFR
MUTATION POSITIVE ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS
IN GREECE
Fragoulakis V1, Pallis A2, Kourlaba G1, Georgoulias V2, Maniadakis N1
1National School of Public Health, Athens, Greece, 2University General Hospital of Herakleio,
Herakleio, Greece
OBJECTIVES: To investigate the cost-effectiveness of Gefitinib relative to the other
alternatives used for the first line treatment of EGFR mutation positive advanced
lung cancer patients, including: gemcitabine/carboplatin, paclitaxel/carboplatin,
vinolerbin/cisplatin, gemcitabine/cisplatin and pemetrexed/cisplatin, from a pro-
vider and payer perspective in Greece METHODS: A probabilistic Markov model
was constructed with four health states: treatment response, stable disease, dis-
ease progression and death. Objective response rates, hazard ratios and utility
decrements for Gefitinib relative to paclitaxel/carboplatin were obtained from a
head-to-head trial (IPASS), while meta-analysis was used to estimate correspond-
ing data for remaining comparators. Utilities were applied to estimate Quality
Adjusted Life Years (QALYs). The databases of several hospitals were analyzed to
estimate resource utilization. Unit prices were obtained from the most up to date
official resources and reflect 2011. Outcomes were bootstrapped 5,000 times to deal
with uncertainty and to construct uncertainty intervals (UI). A discounting rate of
3.5% was applied for all outcomes. RESULTS: Mean QALYs were: 1.10 (95%UI:0.89-
1.28), 1.04 (95%UI:0.87-1.19), 0.95 (95%UI:0.80-1.05), 0.91 (95%UI:0.76-1.10), 0.90
(95%UI:0.77-1.00) and 0.87 (95%UI:0.73-0.99) for gefitinib, pemetrexed/cisplatin,
gemcitabine/cisplatin, gemcitabine/carboplatin, paclitaxel/carboplatin and vi-
nolerbin/cisplatin respectively. From a provider perspective, total treatment cost
per patient was: €61,865 (95%UI:€52,848-€71,444), €72,817 (95%UI:€65,213-€80,014),
€59,270 (95%UI:€52,830-€65,530), €60,842 (95%UI:€50,113-€71,343), €58,081 (95%UI:
€53,237-€62,628) and €54,468 (95%UI:€46,874-€62,245), respectively. Hence, gefinitib
dominates all other options apart from vinolerbin/cisplatin, which is the least
costly option. The incremental cost per QALY gained with gefitinib relative to vi-
nolerbin/cisplatin, was limited to €9,662. Similar were the results from a payer
perspective. The incremental cost per QALY gained in this case was €27,369. Prob-
abilistic analysis indicated that at a 50,000 willingness to pay threshold gefitinib
was cost-effective in 90% of cases in both perspectives of analysis. CONCLUSIONS:
Gefitinib may represent a cost-effective choice, compared with alternative used in
the first line treatment of mutation positive non-small cell lung cancer patients in
Greece.
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COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION FOR
PREVENTION OF CERVICAL CANCER IN RORAIMA, A BRAZILIAN AMAZONIC
REGION STATE
Balbinotto G1, Jardim A2
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OBJECTIVES: : To assess cost-utility of the prophylactic HPV vaccination on the
prevention of ICC in brazilian amazonic regionMETHODS: : A Markov cohort model
was developed as an analytic tool to simulate the natural history of HPV and its
progress to ICC, considering the current preventive programs. Transition probabil-
ities assumptions were based mainly on empirical data of local and national stud-
ies. The model evaluated the addition of the vaccine to 3 cervical cancer screening
scenarios (0, 3 or 10 exams throughout life). RESULTS: : The scenario of three Pap
tests resulted in satisfactory calibration (base case). The addition of HPV vaccina-
tion would reduce by 35% the incidence of ICC, in a setting of 70% vaccination
coverage. The incremental ratio of cost-effectiveness (IRCE) was R$1200 for each
year of quality-adjusted life (QALY) saved. The sensitivity analysis confirms the
robustness of this result, and duration of immunity was the parameter with greater
variation in IRCE. CONCLUSIONS: : Vaccination has a favorable profile in terms of
cost-utility, and its inclusion in the immunization schedule would result in sub-
stantial reduction in incidence and mortality of ICC in amazonic region of Brazil
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COST-UTILITY OF TREATMENT FOR ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
IN CHILDHOOD
Rae CS1, Furlong W2, Sala A3, Jankovic M4, Naqvi A5, Barr RD1
1McMaster University, Hamilton, ON, Canada, 2Health Utilities Inc., Dundas, ON, Canada,
3Azienda Ospedaliera S. Gerardo, Monza, Italy, 4Ospedalo Nuovo S. Gerardo, Monza, Italy, 5The
Hospital for Sick Children, Toronto, ON, Canada
OBJECTIVES: Cost-utility evaluation comparing Dana-Farber Cancer Institute
(DFCI) and Berlin-Frankfurt-Munster (BFM) treatment strategies for childhood ALL.
METHODS: Children treated at 7 centres in Canada, Italy and the USA were eligible
for health-related quality of life (HRQL) assessment using the Health Utilities Index
Mark 3. Parents completed assessments during 4 active treatment phases and at
2-years following therapy. Mean HRQL scores were used to calculate quality-ad-
justed life years (QALYs). Costs were calculated from the perspective of the Ontario
(Canada) health care system. Patients from 2 Ontario centres were eligible for cost-
ing. Service utilization was obtained from Canadian Institute of Health Information
Discharge Abstract Database and National Ambulatory Care Reporting System re-
cords. Standard costs were used for inpatient, outpatient and physician services.
Difference in mean cost was assessed by t-test. The analytical horizon was 5 years
after diagnosis. Future costs and QALYs were discounted at 5% per year. Sensitivity
analyses used 95% confidence bounds (CB) of mean HRQL scores and discount rates
of 0% or 3%. RESULTS:A total of 1281 HRQL assessments were collected. Costs were
measured for 28 DFCI and 66 BFM patients. Based on mean HRQL scores, BFM had
0.17 (0.16 at 3% and 0.03 at 0%) more QALYs than DFCI. On lower CB for BFM and
upper CB of DFCI mean HRQL scores, BFM had 0.16 (0.16 at 3% and 0.03 at 0%) fewer
QALYs than DFCI. Mean costs for BFM ($101484) and DFCI ($98760) did not differ
significantly (p0.777). CONCLUSIONS: The cost-utility evaluation simplified to a
QALY-effectiveness analysis because of no significant difference in mean costs.
Sensitivity analysis indicates that mean QALY estimates are imprecise and overlap
between the two strategies. Therefore, BFM and DFCI are equally QALY-effective
within the range of estimation uncertainty. Future work will focus on diagnostic
sub-groups with more precise cost and QALY estimates.
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